Site notes
This page validates as XHTML 1.0, and will look much better in a browser that supports web standards. So maybe you should...
This page validates as XHTML 1.0, and will look much better in a browser that supports web standards. So maybe you should...
Sender's message:
Sent on Sunday, 2008 Oct 05.
Search breast cancer
Click on the following url to view complete results in pubmed. (Results may change over time.)
http://www.ncbi.nlm.nih.gov/entrez/cubby.fcgi?call=0H3TgiSBYsbg1P_fnsE7NyGqc9KpBlqu9brH9bp0jlXNO4TbSepkyHOhFFrY-70&WebCubbyUser=0dqfhIoHQLwoTEWX7glV2eIG%401EDF6E768E8D6FC0_0016SID
To unsubscribe from these e-mail updates click on the following url
http://www.ncbi.nlm.nih.gov/entrez/cubby.fcgi?call=0t3mnrSQNVN6Nek1cEJXXAolTCye851lJCgHHDhrz88jOQmNR&WebCubbyUser=0dqfhIoHQLwoTEWX7glV2eIG%401EDF6E768E8D6FC0_0016SID
==================== Entrez pubmed Results ======================
Items 1 - 5 of 27
1: Cancer. 2008 Oct 2; [Epub ahead of print]
Sites of distant recurrence and clinical outcomes in patients with metastatic
triple-negative breast cancer: high incidence of central nervous system
metastases.
Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
Massachusetts.
BACKGROUND.: The purpose of the current study was to characterize the outcomes
of patients with metastatic triple-negative breast cancers, including the risk
and clinical consequences of central nervous system (CNS) recurrence. METHODS.:
Using pharmacy and pathology records, a study group of 116 patients who were
treated for metastatic triple-negative breast cancer at Dana-Farber Cancer
Institute between January 2000 and June 2006 was identified. RESULTS.: The
median survival from time of metastatic diagnosis was 13.3 months. Sixteen
patients (14%) were diagnosed with CNS involvement at the time of initial
metastatic diagnosis; overall, 46% of patients were diagnosed with CNS
metastases before death. The median survival after a diagnosis of CNS metastasis
was 4.9 months. The age-adjusted and race-adjusted rate of death for patients
whose first presentation included a CNS metastasis was 3.4 times (95% confidence
interval, 1.9-6.1 times) that of patients without a CNS lesion at the time of
first metastatic presentation. Of the 53 patients who developed brain
metastases, only 3 patients were judged to have stable or responsive systemic
disease in the face of progressive CNS disease at the last follow-up before
death. CONCLUSIONS.: Triple-negative breast cancer is associated with poor
survival after recurrence. CNS recurrence is common, but death as a direct
consequence of CNS progression in the setting of controlled systemic disease is
uncommon. Thus, it does not appear that the high rate of CNS involvement is
because of a sanctuary effect, but rather is due to the lack of effective
therapies in general for this aggressive subtype of breast cancer. New treatment
strategies are needed. Cancer 2008. (c) 2008 American Cancer Society.
PMID: 18833576 [PubMed - as supplied by publisher]
2: Fortschr Neurol Psychiatr. 2008 Oct;76(10):583-93. Epub 2008 Oct 2.
[Psychometric evaluation of a neuropsychological test battery measuring
cognitive dysfunction in cancer patients - recommendations for a screening
tool.]
[Article in German]
Scherwath A, Poppelreuter M, Weis J, Schulz-Kindermann F, Koch U, Mehnert A.
Institut und Poliklinik fur Medizinische Psychologie, Zentrum fur Psychosoziale
Medizin, Universitatsklinikum Hamburg-Eppendorf (Komm. Direktorin: Prof. Dr. M.
Bullinger).
Cognitive dysfunctions in cancer patients as a consequence of various oncologic
treatments (e. g. chemotherapy) have been increasingly described within the
current literature. As most of the neuropsychological tests used within those
studies have been developed and validated in neurologic or psychiatric patient
populations, it remained unclear whether the application of such measures would
be appropriate in cancer patients as well. The present study focused on the
psychometric evaluation of a neuropsychological test battery that had been used
in two empirical studies carried out at the Department of Medical Psychology,
University Medical Center Hamburg-Eppendorf. In addition, recommendations for a
basic screening tool were developed. Both study samples were analyzed
separately. One sample included breast cancer patients an average of five years
following treatment; the second sample included patients with hematological
malignancies which had been tested before and 100 days after stem cell
transplantation. A further data set of a mixed cancer population (breast cancer
patients and patients with hematological malignancies) and corresponding
neuropsychological measures could be used for the replication of our results.
Those patients had been investigated during an intervention study while
receiving rehabilitation at the Clinic for Tumor Biology in Freiburg. Results
show that primarily measures for attention were found to have satisfying to high
reliability and contribute independently to the explanation of variance of
neuropsychological dysfunctions after cancer treatment. In particular, the
subtest "Alertness" of the Test Battery for Attentional Performance (TAP) can be
recommended as a basic screening for the assessment of cognitive dysfunctions in
breast cancer patients and patients with hematological malignancies.
Publication Types:
English Abstract
PMID: 18833503 [PubMed - in process]
3: Rev Lat Am Enfermagem. 2008 Aug;16(4):733-738.
Participating in a support group: experience lived by women with breast cancer.
Pinheiro CP, Silva RM, Mamede MV, Fernandes AF.
Faculdade Integrada do Ceara, Brasil.
The goal of the study was to understand the meaning of support groups in the
life of women with breast cancer. It is a qualitative study with 30
mastectomized women who belonged to six support groups in the city of Fortaleza,
Ceara. Data were collected with semi-structured interviews, organized and
analyzed based on the interactionism concept. The results characterized the
support groups as a mechanism to cope with the situation and to overcome the
suffering derived from the diagnosis and treatment of the breast carcinoma. The
socialization of the experiences facilitated the search for assistance in the
support groups, since sharing the problems with mastectomized women was a way to
preserve a high self-esteem, have faith and overcome some difficulties.
Participating in the group provided well-being and a differentiated care, since
it was considered a way to know, accept and understand the disease and its cure,
facilitating the socialization of ideas.
PMID: 18833456 [PubMed - as supplied by publisher]
4: G Ital Dermatol Venereol. 2008 Apr;143(2):157-60.
Zuska's disease.
Guadagni M, Nazzari G.
Dermatology Operative Unit, S. Andrea Hospital, La Spezia, Italy
massimo.guadagni@ausl5.liguria.it.
Cutaneous signs and symptoms in subareolar abscesses of the breast or
lactiferous fistula (Zuska's disease, ZD) are common and frequent, but generally
dermatologist ignore this clinical entity. An epithelial squamous metaplasia
causes plugging and obstruction of the ducts is a pathogenetic event. Subsequent
inflammatory reaction and infection produce local and general symptoms. Nipple
retraction, recurrent episodes of erysipela and presence of painful nodules
under the areola in a non-lactating woman are suspect. The presence of a milky
draining sinus in the areola is characteristic. The diagnostic challenge is to
differentiate these benign condition from a breast cancer. Treatment with
antibiotics in the acute and chronic phase is mandatory, surgical removal of
abscess and duct is sometimes resolutive. The authors describe a case of ZD in a
pathologically obese woman treated with a long term penicillin schedule with no
favorable effects.
PMID: 18833042 [PubMed - in process]
5: Am J Pathol. 2008 Oct 2; [Epub ahead of print]
Focal Adhesion Kinase-Related Proline-Rich Tyrosine Kinase 2 and Focal Adhesion
Kinase Are Co-Overexpressed in Early-Stage and Invasive ErbB-2-Positive Breast
Cancer and Cooperate for Breast Cancer Cell Tumorigenesis and Invasiveness.
Behmoaram E, Bijian K, Jie S, Xu Y, Darnel A, Bismar TA, Alaoui-Jamali MA.
From the Departments of Medicine, Oncology and Pathology,* Lady Davis Institute
of the Sir Mortimer B. Davis Jewish General Hospital, McGill University,
Montreal, Canada; and the Department of Pathology and Laboratory Medicine,
Rockyview General Hospital, and Department of Medicine, University of Calgary,
Calgary, Canada.
Early cancer cell migration and invasion of neighboring tissues are mediated by
multiple events, including activation of focal adhesion signaling. Key
regulators include the focal adhesion kinase (FAK) and FAK-related proline-rich
tyrosine kinase 2 (Pyk2), whose distinct functions in cancer progression remain
unclear. Here, we compared Pyk2 and FAK expression in breast cancer and their
effects on ErbB-2-induced tumorigenesis and the potential therapeutic utility of
targeting Pyk2 compared with FAK in preclinical models of breast cancer. Pyk2 is
overexpressed in tissues from early and advanced breast cancers and
overexpressed with both FAK and epidermal growth factor receptor-2 (ErbB-2) in a
subset of breast cancer cases. Down-regulation of Pyk2 in ErbB-2-positive,
FAK-proficient, and FAK-deficient cells reduced cell proliferation, which
correlated with reduced mitogen-activated protein kinase (MAPK) activity. In
contrast, Pyk2 silencing had little impact on cell migration and invasion. In
vivo, Pyk2 down-regulation reduced primary tumor growth induced by a metastatic
variant of ErbB-2-positive MDA 231 breast cancer cells but had little effect on
lung metastases in contrast to FAK down-regulation. Dual reduction of Pyk2 and
FAK expression resulted in strong inhibition of both primary tumor growth and
lung metastases. Together, these data support the cooperative function of Pyk2
and FAK in breast cancer progression and suggest that dual inhibition of FAK and
Pyk2 is an efficient therapeutic approach for targeting invasive breast cancer.
PMID: 18832579 [PubMed - as supplied by publisher]